We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+38.63%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$566M
AUM Growth
-$36.9M
Cap. Flow
-$112M
Cap. Flow %
-19.7%
Top 10 Hldgs %
52.22%
Holding
76
New
5
Increased
6
Reduced
14
Closed
25

Top Buys

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$20.6M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.7M
3
ZLAB icon
Zai Lab
ZLAB
+$9.29M
4
OMER icon
Omeros
OMER
+$8.48M
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$7.71M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$23.5M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$22.9M
3
BPMC
Blueprint Medicines
BPMC
+$15.7M
4
BLUE
bluebird bio
BLUE
+$14.8M
5
NVRO
NEVRO CORP.
NVRO
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTVA
26
MetaVia Inc
MTVA
$7.44M
$7.55M 1.33%
12
-2
-14% -$1.59M
INDP icon
27
Indaptus Therapeutics
INDP
$192M
$7.25M 1.28%
362
– –
ABEO icon
28
Abeona Therapeutics
ABEO
$369M
$6.82M 1.2%
16,000
– –
SGMO
29
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$6M 1.06%
400,000
– –
JNCE
30
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$5.61M 0.99%
359,738
– –
AGRX
31
DELISTED
Agile Therapeutics
AGRX
$5.58M 0.98%
625
– –
BPMC
32
DELISTED
Blueprint Medicines
BPMC
$5.22M 0.92%
75,000
-292,900
-80% -$15.7M
MRSN
33
DELISTED
Mersana Therapeutics
MRSN
$5.11M 0.9%
11,822
+8,630
+270% +$3.4M
AAAP
34
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$5.07M 0.9%
75,000
– –
NERV icon
35
Minerva Neurosciences
NERV
$187M
$4.62M 0.82%
75,988
-173,689
-70% -$9.96M
WVE icon
36
Wave Life Sciences
WVE
$1.11B
$4.39M 0.78%
202,079
– –
SYRS
37
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.36M 0.77%
29,630
– –
CBAY
38
DELISTED
Cymabay Therapeutics
CBAY
$4.03M 0.71%
+500,000
New +$3.38M
CFRX
39
DELISTED
ContraFect Corporation
CFRX
$3.94M 0.7%
4,438
– –
ARDX icon
40
Ardelyx
ARDX
$1.25B
$3.21M 0.57%
572,738
-850,000
-60% -$4.48M
COLL icon
41
Collegium Pharmaceutical
COLL
$1.17B
$3.15M 0.56%
300,000
– –
TRIL
42
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.09M 0.55%
600,000
– –
IMDZ
43
DELISTED
Immune Design Corp.
IMDZ
$2.9M 0.51%
280,500
-56,500
-17% -$556K
XLRN
44
DELISTED
Acceleron Pharma
XLRN
$2.8M 0.49%
75,000
– –
OVID icon
45
Ovid Therapeutics
OVID
$442M
$1.92M 0.34%
223,972
– –
CTMX icon
46
CytomX Therapeutics
CTMX
$714M
$1.82M 0.32%
100,000
-130,000
-57% -$2.03M
CRIS icon
47
Curis
CRIS
$9.67M
$1.71M 0.3%
575
-425
-43% -$1.57M
OTLK icon
48
Outlook Therapeutics
OTLK
$194M
$814K 0.14%
3,712
-2,554
-41% -$465K
ONSIW
49
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$51K 0.01%
416,666
– –
ONSIZ
50
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$21K ﹤0.01%
416,666
– –
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Cormorant Asset Management held 76 positions worth $566M, down 6.1% from $603M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Cormorant Asset Management withdrew a net $112M in Q3 2017, closing 25 positions and reducing 14 holdings. Its most notable exit was Lakefront Biotherapeutics American Depositary Shares, an estimated $22.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 84% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock worth $12.1M.

  • Cormorant Asset Management's largest Q3 2017 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 388,574 shares worth $12.1M.
  • Cormorant Asset Management added most to Ignyta, Inc. in Q3 2017, an estimated $20.6M increase.
  • Cormorant Asset Management's biggest Q3 2017 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $23.5M.
  • Cormorant Asset Management fully exited Lakefront Biotherapeutics American Depositary Shares in Q3 2017, selling an estimated $22.9M.
  • Cormorant Asset Management's ten largest holdings make up 52% of its $566M portfolio in Q3 2017.
  • Cormorant Asset Management opened 5 new positions and closed 25 in Q3 2017.
  • Cormorant Asset Management's portfolio value fell 6.1% quarter-over-quarter to $566M.

Based on Cormorant Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.